StockWatch
·
THYROCARE · Q2 FY27 · THE VERDICT

Growth Strong, But Profits Buried Under ₹45 Crore Write-Off

Revenue surged 25% and franchisees hit a 3-year high, but reported profit collapsed 68% due to a one-time NHL impairment. The organic story is far cleaner—and the market is already pricing in the recovery.

Q2 FY27 resultsTHYROCAREThyrocare Technologies Ltd02 Nov 2026 · 6 min read
Reported PAT

₹15.2 Cr

-68.2% YoY

Pre-exception PAT

₹60 Cr

+26% YoY

NHL impairment

₹45 Cr

goodwill write-off

The headline tension: where consolidated profit actually went

Thyrocare delivered ₹270.8 Cr in revenue—a 25.1% beat on the prior year and right in line with the 15–20% guidance range it reiterated on the Q1 call. Operationally, the quarter is a success. But reported net profit landed at ₹15.2 Cr, down 68.2% year-on-year, a number so far below the momentum that management felt compelled to lead the call with a pre-exception figure of ₹60 Cr. That 45-crore-rupee gap is a ₹45 Cr goodwill impairment on the NHL (Nuclear Healthcare) business, which Thyrocare acquired in Q1 FY27 and is now divesting at a loss. The write-off is non-cash, disclosed in full, and entirely explained—but the optics matter. A 25% revenue quarter that reports a 68% profit decline risks being read as deterioration rather than capital discipline.

Q2 FY27 PAT, ₹ Cr
022.444.867.215.2Reported (consolidated)45NHL write-off60Pre-exception (ex-NHL)
The ₹45 Cr impairment is 75% of the reported PAT shortfall. Adjusted for the write-off, profit is up 26% YoY—a very different picture.

Where the growth actually came from

Management's on-call claims vs. what the numbers confirm

Pathology business grew 27% YoY in Q2

Delivered result

Franchise revenue +27% YoY (₹139 Cr). Consolidated pathology revenue implicit in 25.1% overall growth.

Verdict

Supported

PAT margin 22% (₹60 Cr profit) before exceptions, up 26% YoY

Delivered result

Consolidated reported PAT ₹15.2 Cr (5.5% margin), down 68.2% YoY. Pre-exception PAT ~₹60 Cr aligns with claim.

Verdict

Technically accurate, tonally misleading (consolidated hides the write-off)

EBITDA margin 33% with 25% YoY growth; gross margin 74.2%

Delivered result

Delivered ₹89 Cr EBITDA (33% margin, +25% YoY). Operating margin 16.4%; gross margin 74.2% plausible on volume lift.

Verdict

Supported

Franchisee additions of 1,180 in Q2, highest in 3 years; active base 12,911

Delivered result

Delivered exactly: 1,180 net adds, base 12,911. On track for FY27 guidance of 1,700 gross (Q2 seasonally represents ~700 of 1,700).

Verdict

Supported

Specialty diagnostic platform now commercially live with momentum

Delivered result

Pregnancy test kit launched in May; 4% of pathology revenue achieved by Q2. Allergy, genomics in pipeline. ₹1.5 Cr launch investment Q2.

Verdict

Supported (early-stage, unproven execution)

What changed on this call

The bull-bear ledger

  • Revenue growth 25% exceeds guidance; core pathology (franchisee + partnership) both growing 27%+

  • Franchisee base 12,911 with record 1,180 adds in Q2; asset-light model is scaling

  • EBITDA margin 33% on 25% growth shows operational leverage; no margin compression

  • Operating cash flow ₹133 Cr in H1 FY27; strong cash generation despite growth investment

  • Specialty diagnostics launch on schedule; pregnancy kit in 10,000 chemists; new growth vector

  • Reported PAT collapsed 68% despite operational success; optics damage from NHL write-off

  • Specialty is 4% of revenue today; target 10–15% within 3–5 years is unproven ramp

  • Franchisee productivity per unit at risk if saturation sets in; churn not quantified

  • API Group (51% stake) still loss-making; profitability milestone Q4 FY27 not yet hit

  • Management led call with pre-exception profit; buried consolidated miss—tonally defensive

Risks, ranked by how much they should concern a holder

Where the real earnings risk sits

Specialty diagnostics ramp is unproven

HIGH

Only 4% of revenue today; ambition to reach 10–15% within 3–5 years. ₹1.5 Cr launch expense Q2; heavy marketing spend required. Product-market fit unclear; no profitability timeline disclosed. If clinical adoption stalls or margins compress, it becomes a margin drain, not a growth engine.

Franchisee growth may not sustain at elevated levels

MEDIUM

1,180 adds in Q2 is a pull-forward of peak-season effort. Q3 is seasonally weak; management already cautioned 'do not anticipate significant Q3 additions.' If Q3–Q4 revert to 300–400 adds/quarter, FY27 will miss the 1,700 guidance. Churn not quantified; net additions could mask rising attrition.

Pre-exception profit narrative masks consolidation stress

MEDIUM

Management led with ₹60 Cr pre-exception PAT while consolidated result was ₹15.2 Cr. While technically transparent (the impairment is disclosed), the tone is defensive and risks erosion of earnings-quality trust if similar one-time items recur. NHL was strategic; API is next—if API also impairs, perception will harden.

API Group profitability delayed beyond Q4 FY27

MEDIUM

51% stake still loss-making. Management guided API to turn profitable Q4 FY27; if this slips, further write-downs are likely. At that point, the strategic option (IPO or reverse merger) faces headwinds. Opportunity cost of capital in the meantime.

Macro slowdown hits partnership/B2B volumes

LOW-MEDIUM

Partnership segment (insurance, corporate health, online aggregators) is 49% of revenue. PharmEasy alone is 11% of partnership revenue. If macro weakens, B2B growth could compress faster than B2C (franchisee) growth, pulling consolidated CAGR below the 15–20% guidance.

How the street is positioned—and what it tells us

The stock is trading at ₹456.3, down 31% from its all-time high of ₹662 but up 33% from its 52-week low of ₹342.55. It is trading below its 20-day average (₹494.82), 50-day average (₹540.2), and 200-day average (₹486.53)—a classic setup where the short-term technicals are weak but longer-term trend is still intact. RSI sits at 35.8 (neutral, mildly oversold), signaling neither panic nor complacency. Volume is increasing, a sign that traders are engaged despite the price pressure.

The post-result action confirms the fundamental read. The stock did not pop on the result (which would have been expected if 25% growth and record franchisee adds had surprised). Instead, the market punished the consolidated PAT headline, treating it as a deterioration rather than the capital-discipline story it is. That the stock has stabilized above ₹456 (vs. panic-selling below ₹400) suggests institutional buyers have stepped in, betting that the organic story—25% growth, operational leverage, franchisee momentum—will eventually outweigh the one-time NHL noise.

Institutional positioning backs this thesis. FII ownership stands at 5.44% (up 7 basis points quarter-on-quarter), while DII is flat at 20.92%. More telling: the past ~6 months of bulk and block deals show a parade of institutional buying: Kotak Mahindra Life (24L shares @ ₹624), HBM Healthcare Investments (7.61L @ ₹624), ICICI Prudential (8.01L + 8.01L @ ₹624 across two blocks), DSP Mutual Fund (13.21L @ ₹624), and WhiteOak Capital (6.41L @ ₹624). These are not panic trades; they are steady accumulation near the ₹624 level, which is 27% above the current stock price. The message: smart money is front-running a recovery once the NHL narrative fully clears.

One yellow flag in the order flow: DOCON Technologies (a promoter-linked entity) has sold 10L+ shares near ₹631.71 and ₹624 in the same timeframe. Promoter selling near the highs is a contrarian signal, especially when institutions are buying lower. This warrants watching—if DOCON continues to trim, it could signal internal concern about near-term momentum or capital redeployment outside the core business.

The debate

What to watch next

  • 1 · Q3 & Q4 franchisee additions

    Management warned Q3 is seasonally weak. If Q3 adds fall below 200 net (a sign of deceleration), FY27 will miss the 1,700 guidance. Watch for churn metrics; if average-franchisee retention is <95%, the growth story shifts from expansion to saturation.

  • 2 · Specialty diagnostics revenue ramp

    Pregnancy kit is in 10,000 chemists; allergy and genomics tests are in pipeline. By Q4 FY27, specialty should be >5% of pathology revenue if traction is real. If it stays stuck at 4%, the whole high-margin hypothesis is in question. Watch for gross margin on specialty vs. core pathology; if specialty's margin is 100+ bps below core, the ramp becomes accretive to growth but dilutive to profitability.

  • 3 · API Group profitability (Q4 FY27 target)

    Management reiterated API should turn profitable Q4 FY27 ex-Thyrocare. If this slips into Q1/Q2 FY28, risk of another write-down rises. Conversely, if API hits profitability on schedule, strategic options (IPO, reverse merger) open and unlock a value event.

  • 4 · DOCON Technologies selling pattern

    Promoter-linked entity has trimmed 10L+ shares near the highs. Watch whether this is opportunistic (one-off tax-loss harvest or liquidity need) or a signal of internal concern. If DOCON trims another 10L+ shares in coming months, elevation to caution is warranted.

The number to track from here

Organic PAT—pre-exception, consolidated—is the single most important metric going forward. It should grow 20–25% in FY27 if guidance holds (₹60 Cr in Q2 implies an ~₹220 Cr full-year run-rate). If organic PAT stalls below 15% growth in Q3 or Q4, the growth narrative is broken, and the stock re-rates lower. Conversely, if organic PAT grows 25%+ throughout FY27 and specialty becomes 6–8% of portfolio, the stock has room to re-rate toward ₹550–600 as investors regain confidence in management execution.

Thyrocare's Q2 is a quarter of solid operational execution undermined by one-time accounting noise. The core business—franchisee growth, operational leverage, international expansion—is on track. But the transition to a multi-vector platform (specialty, consumer products, API optionality) is unproven, and the ₹45 Cr NHL write-off signals that not every strategic bet will work. For holders, patience through Q3–Q4 is warranted; the specialty ramp and API profitability will resolve the debate by year-end. For new buyers at current levels, the setup is compelling only if you have a 3–5 year horizon and belief in the specialty opportunity. The number to track is organic PAT—if it sustains 20–25% growth, the stock will find its way above ₹500. If it doesn't, the drawdown from ₹662 is not over.

Informational and educational content only. Not investment advice.